Biocartis Oncology Tests


Cancer is a large group of diseases that can occur in any tissue or organ of the body and can spread to adjacent tissues or distant tissues where cells multiply uncontrollably. Its treatment still remains a major challenge. Because cancer cells fight with therapeutic agents, develop new mechanisms to adapt to them and change their formation mechanisms.


Who is it applied to, what diseases does it cover?

  • In different types of cancer, mainly lung, breast and colon cancer:
  • From tissue: KRAS, NRAS, BRAF, EGFR, Gene fusion panel, BRAF, Microsatellite instability (MSI)
  • From liquid biopsy: EGFR, BRAF, KRAS mutations can be detected.

What samples is it made of?

It can be studied from solid tissue and blood samples.

Why should it be done?

Rapid initiation of immunotherapy or targeted therapy as first-line therapy improves overall survival rates. Therefore, timely detection of biomarkers is very important.

Detection of relevant cancer mutations reveals the mutation profile of the cancer. It provides the patient with the earliest and most effective chemotherapy option possible. Thus, it shortens the time to start treatment in fast-growing aggressive tumors. It also reduces the anxiety of the patient while waiting for the results.

What are the advantages?

  • It is an advanced, standardized and automated technology.
  • Next generation sequencing (NGS) gives results much faster than Pyrosequencing and conventional PCR methods. It can detect mutations on the same day.
  • It enables the physician to make a quick decision and guides the treatment selection.
  • It has high sensitivity.
  • It can be studied from both tissue and blood samples.